The construction plans of the two innovative functional platforms of Biopharmaceutical R & D Platform and International Joint Innovation Research Center for Gene Editing and Cell Therapy built by the Joint Technological Institute and Minhang District of Shanghai have been written into the Implementation Plan and Three-year Action Plan of Minhang national demonstration zone for the transformation of scientific and technological achievements.
Shanghai Xiangyao Biotechnology Co., Ltd., the first alumni business incubation project based on the two platforms, has been on track and achieved the goal of making profits after one year of establishment. In 2020, the enterprise won the Outstanding Work Award in the University Exhibition Group of the 22nd China International Industry Expo, and Shanghai’s Best Scientific and Technological Innovation Award in the Maker China. Additionally, it entered the list of 2020 Shanghai's top 50 entrepreneurial enterprises with the most investment potential, and established the Xiangyao Biological Innovation and Entrepreneurship Fund with the Academy of Life Sciences of ECNU. In 2021, Xiangyao was a nominee in the 10th China Innovation and Entrepreneurship Competition (the growing enterprise group) and was awarded as Cutting-edge Enterprise of S&T entrepreneurship in Minhang District in 2021.
On April 1st, 2021, the unveiling ceremony of Zizhu base of National University Science Park of East China Normal University was successfully held in Zizhu International Education Park. It is jointly built by ECNU’s Science Park and CTO, and will take the positioning of Life Science and Intelligent Education Industry, and attract alumni related innovation and entrepreneurship projects to settle in and conduct high-end talent cultivation practice. The projects will take the advantages of the research achievements in the fields of Life Science, Humanities such as Pedagogy and Psychology, as well as Intelligent Research such as Brain Science and Software Engineering. Currently, the enterprise projects incubated on the platform include YaoTang (Shanghai) Biotechnology Co., Ltd., Shanghai HuanChuang Network Technology Co., Ltd., Shanghai YuanXin Biomedical Technology Co., Ltd. and XingKong Laser Technology (Shanghai) Co., Ltd.
